FDA approves Forest's aclidinium bromide

FDA approved late Monday an NDA from Forest Laboratories Inc. (NYSE:FRX) for Tudorza Pressair aclidinium bromide for the long-term maintenance treatment of bronchospasm associated with chronic obstruc...